 Connection
Rohit Katial to Treatment Outcome
This is a "connection" page, showing publications Rohit Katial has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.389 |
|
|
|
-
Hoyte FC, Katial RK. Antihistamine therapy in allergic rhinitis. Immunol Allergy Clin North Am. 2011 Aug; 31(3):509-43.
Score: 0.031
-
Katial RK, Bernstein D, Prazma CM, Lincourt WR, Stempel DA. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy Asthma Proc. 2011 Mar-Apr; 32(2):127-36.
Score: 0.030
-
Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010 Oct; 126(4):738-44.
Score: 0.029
-
Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan-Feb; 31(1):68-75.
Score: 0.028
-
Wang E, Henley W, Larenas-Linnemann D, Bulathsinhala L, Tran TN, Wechsler ME, Aaron SD, Al-Ahmad M, Al-Lehebi R, Altraja A, Barker P, Beastall A, Belevskiy AS, Bergeron C, Bjermer L, Björnsdóttir US, Bosnic-Anticevich SZ, Bourdin A, Brusselle GG, Busby J, Canonica GW, Carter V, Chapman KR, Chapman N, Christoff GC, Cosio BG, Costello RW, Fingleton J, Fonseca JA, Gaga M, Gibson PG, Hansen S, Heaney LG, Heffler E, Hew M, Horiguchi T, Hoyte F, Hubbard RB, Iwanaga T, Jackson DJ, Katial R, Koh MS, Kostikas K, Kuna P, Lehmann S, Lehtimäki L, Louis R, Lúdvíksdóttir D, Lugogo N, Mahboub B, Martin N, Máspero J, Menzies-Gow AN, Mohan A, Murray RB, Nagano T, Papadopoulos NG, Papaioannou AI, Patel PH, Perez-de-Llano L, Perng DW, Peters MJ, Pfeffer PE, Pitrez PM, Pleasants RA, Popov TA, Porsbjerg CM, Puggioni F, Quinton A, Rhee CK, Sadatsafavi M, Salvi S, Scioscia G, Sheu CC, Sirena C, Taillé C, Taube C, Torres-Duque CA, Tsai MJ, Tunsäter A, Ulrik CS, Price DB. Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach. J Allergy Clin Immunol Pract. 2025 Dec; 13(12):3296-3315.
Score: 0.021
-
Pavord I, Katial RK, Jackson DJ, Rogers L, Lega Hoyte FC, Smolen J, Wechsler ME, Akuthota P, Jackson DJ. Current data on biologics: Evaluating clinical remission in asthma. J Allergy Clin Immunol. 2025 Sep; 156(3S):S15-S19.
Score: 0.021
-
Poole JA, Nanda A, Matangkasombut P, Katial RK. Food intolerance, flushing, and diarrhea in a 44-year-old woman. Ann Allergy Asthma Immunol. 2005 Jun; 94(6):621-6.
Score: 0.020
-
Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024 Oct 01; 210(7):869-880.
Score: 0.019
-
Gauvreau GM, Sehmi R, FitzGerald JM, Leigh R, Cockcroft DW, Davis BE, Mayers I, Boulet LP, Al-Sajee D, Salter BM, Cusack RP, Ho T, Whetstone CE, Alsaji N, Satia I, Killian KJ, Mitchell PD, Magee IP, Bergeron C, Bhutani M, Werkström V, Durzynski T, Shoemaker K, Katial RK, Jison M, Newbold P, McCrae C, O'Byrne PM. Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial. Eur Respir J. 2024 Sep; 64(3).
Score: 0.019
-
Rivera O, Katial R, Hoyte FCL. Biologics in Asthma: Potential to Achieve Clinical Remission. Immunol Allergy Clin North Am. 2024 11; 44(4):725-736.
Score: 0.019
-
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024 Jul; 64(1).
Score: 0.019
-
Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, Al-Ahmad M, Al-Lehebi R, Altraja A, Beastall A, Bergeron C, Bjermer L, Bjerrum AS, Cano-Rosales DJ, Canonica GW, Carter V, Charriot J, Christoff GC, Cosio BG, Denton E, Fernandez-Sanchez MJ, Fonseca JA, Gibson PG, Goh C, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann D, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Patel P, Perez-De-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2347-2361.
Score: 0.019
-
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ. Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary. Immunotherapy. 2024; 16(10):641-648.
Score: 0.019
-
Li X, Newbold P, Katial R, Hirsch I, Li H, Martin UJ, Meyers DA, Bleecker ER. Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. J Allergy Clin Immunol Pract. 2024 Oct; 12(10):2732-2743.
Score: 0.019
-
Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Lawkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, Price DB. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024; 15:1361891.
Score: 0.019
-
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ. Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. J Eur Acad Dermatol Venereol. 2023 10; 37(10):e1211-e1214.
Score: 0.018
-
Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019 02; 7(2):589-596.e3.
Score: 0.013
-
Que LG, Yang Z, Lugogo NL, Katial RK, Shoemaker SA, Troha JM, Rodman DM, Tighe RM, Kraft M. Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. Immun Inflamm Dis. 2018 06; 6(2):322-331.
Score: 0.012
-
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov; 132(5):1086-1096.e5.
Score: 0.009
-
Murray JJ, Weiler JM, Schwartz LB, Busse WW, Katial RK, Lockey RF, McFadden ER, Pixton GC, Barrett RJ. Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ Cardiovasc Imaging. 2009 Nov; 2(6):492-8.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|